CompletedNCT00246285
About this title
A Study of the Effectiveness and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia
Read the official source — NCT00246285What is this study about?This study evaluated the safety and effectiveness of risperidone for people with schizophrenia.
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 13–17
- Countries
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
CompletedNCT00250367
About this title
A Study of the Effectiveness and Safety of Risperidone Versus Placebo as add-on Therapy to Mood Stabilizers, in the Treatment of Manic Episodes Associated With Bipolar Disorder.
Read the official source — NCT00250367What is this study about?This study evaluated the safety and effectiveness of risperidone for people with bipolarity.
This study has finished and is no longer accepting participants.
Location not clearly listedBipolarityMedication studyAges 18–65
- Countries
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
CompletedNCT00257075
About this title
A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Manic Episodes Associated With Bipolar I Disorder
Read the official source — NCT00257075Official study titleThe Efficacy And Safety Of Flexible Dosage Ranges Of Risperidone Versus Placebo In The Treatment Of Manic Episodes Associated With Bipolar I Disorder.
This study has finished and is no longer accepting participants.
Location not clearly listedBipolarityMedication studyAges 18+
- Countries
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
CompletedNCT00249236
About this title
A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder
Read the official source — NCT00249236Official study titleThe Efficacy And Safety Of Flexible Dosage Ranges Of Risperidone Versus Placebo In The Treatment Of Manic Or Mixed Episodes Associated With Bipolar I Disorder
This study has finished and is no longer accepting participants.
Location not clearly listedBipolarityMedication studyAges 18+
- Countries
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
TerminatedNCT00287742
Official study titleDouble-blind, Placebo-controlled Clinical Trial of JK6476 (Risperidone) in Patients With Hallucinations and Delusions Associated With Alzheimer's Disease
This study ended early.
Location not clearly listedSchizophreniaMedication study
- Countries
- Sponsor
- Janssen Pharmaceutical K.K.
CompletedNCT00210808
About this title
A Study of the Effectiveness and Safety of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity
Read the official source — NCT00210808Official study titleA Multicenter, Randomized, Double-blind, Placebo-controlled, Flexible-dose Study to Assess the Safety and Efficacy of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity
This study has finished and is no longer accepting participants.
Location not clearly listedEating disordersMedication studyAges 18–65
- Countries
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
CompletedNCT00240721
About this title
A Study of the Effectiveness and Safety of Topiramate in the Treatment of Patients With Bipolar Disorder
Read the official source — NCT00240721What is this study about?This study evaluated the safety and effectiveness of topiramate for people with bipolarity.
This study has finished and is no longer accepting participants.
Location not clearly listedBipolarity, SchizophreniaMedication studyAges 16+
- Countries
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
CompletedNCT02430935
Official study titleA Study of the Effectiveness of Cognitive Adaptation Training in Early Intervention for Psychosis
This study has finished and is no longer accepting participants.
In TorontoSchizophreniaBehavioural studyAges 16–29
- Countries
- Canada
- Sponsor
- Centre for Addiction and Mental Health (Hospital / academic medical center)
CompletedNCT00791713
Official study titleA Randomized, Open-label, Single-center, Crossover Study of the Potential Effects of Paroxetine on the Pharmacokinetics of a Single Dose of Paliperidone Extended-release in Healthy Men
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18–55
- Countries
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
CompletedNCT00236379
About this title
A Study of the Effects of Risperidone and Olanzapine on Blood Glucose (Sugar) in Patients With Schizophrenia or Schizoaffective Disorder
Read the official source — NCT00236379Official study titleA Six-month, Double-blind, Randomized, International, Multicenter Trial to Evaluate the Glucoregulatory Effects of Risperidone and Olanzapine in Subjects With Schizophrenia or Schizoaffective Disorder
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18–65
- Countries
- Sponsor
- Janssen, LP
CompletedNCT00538070
About this title
A Study of the Effects of Sarcosine on Symptoms and Brain Glycine Levels in People With Schizophrenia
Read the official source — NCT00538070Official study titleThe Effects of Glycine Transport Inhibition on Brain Glycine Concentration
This study has finished and is no longer accepting participants.
Multiple locations, including BelmontSchizophreniaPlacebo comparisonAges 18–65
- Countries
- United States
- Sponsor
- Massachusetts General Hospital (Hospital / academic medical center)
CompletedNCT00649064
About this title
A Study of the Effects of Ziprasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Patients Who Were Switched From Other Antipsychotic Drugs
Read the official source — NCT00649064Official study titleA Multi-Center Study To Examine The Clinical Effects Of Cross Titration Of Antipsychotics With Ziprasidone In Subjects With Schizophrenia Or Schizoaffective Disorder
This study has finished and is no longer accepting participants.
Multiple locations, including ChanghuaSchizophreniaMedication studyAges 18–65
- Countries
- Taiwan
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
